FDA Oncology Announcements

Anti-VEGFR × Other × Clear all

10 Announcements

FDA approves first biosimilar for cancer treatment

Drugs: Mvasi (bevacizumab-awwb) · Anti-VEGFR antibody, Avastin (bevacizumab) · Anti-VEGFR antibody

Ramucirumab (Cyramza)

Drugs: Cyramza (ramucirumab) · Anti-VEGFR antibody, docetaxel · Taxane, paclitaxel · Taxane

Bevacizumab solution in combination with Paclitaxel

Drugs: Avastin (bevacizumab solution for intravenous infusion) · Anti-VEGFR antibody, Avastin (intravenous infusion) , paclitaxel · Taxane

Ramucirumab in combination with paclitaxel

Drugs: Cyramza (ramucirumab) · Anti-VEGFR antibody, paclitaxel · Taxane

Bevacizumab solution

Drugs: Avastin (bevacizumab solution for intravenous infusion) · Anti-VEGFR antibody, Avastin (intravenous infusion)

Ramucirumab

Drug: Cyramza (ramucirumab) · Anti-VEGFR antibody

Bevacizumab

Drug: Avastin (bevacizumab) · Anti-VEGFR antibody

Bevacizumab (Avastin) in Combination with Interferon Alfa

Drugs: Avastin (bevacizumab) · Anti-VEGFR antibody, interferon alfa

Bevacizumab Injection

Drug: Avastin (bevacizumab) · Anti-VEGFR antibody

Bevacizumab Granted Accelerated Approval

Drugs: Avastin (bevacizumab) · Anti-VEGFR antibody, paclitaxel · Taxane